球内注药对增殖性糖尿病视网膜病变玻璃体液中VEGI表达的影响
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:

陕西省科技研究发展(攻关)计划(No.2004K16-G8); 陕西省社会发展攻关计划(No.2013k12-17-02)


Effects of intravitreous injection on the expression of vascular endothelial growth inhibitor in vitreous of proliferative diabetic retinopathy
Author:
Affiliation:

Fund Project:

Shaanxi Provincial Science and Technology Research and Development(Research)Program(No. 2004K16-G8); Shaanxi Provincial Social Development Research Program(No.2013k12-17-02)

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:探讨球内注药对增殖性糖尿病视网膜病变患者玻璃体液中血管内皮生长抑制因子(vascular endothelial growth inhibitor, VEGI)及其相关因子的影响,评价VEGI与糖尿病视网膜病变的相关性。

    方法:增殖期糖尿病视网膜病变患者50例68眼,按照治疗选择的自然状态分为两组,试验1组34例41眼:球内注射贝伐单抗1.25mg(0.05mL)/次,试验2组16例27眼球内注射曲安奈德4mg(0.1mL)/次,两组分别于球内注药前及注药后1,3,6mo再次注药或行玻璃体切割前抽取玻璃体液0.3mL,并以黄斑裂孔患者20例20眼为空白对照组,注药后根据一定纳入标准,选取各试验组符合条件的患者采集的标本行酶联免疫吸附试验检测VEGI、IL-1β及VEGF的质量浓度,并进行组间比较,所得数据采用SPSS19.0统计软件分析。

    结果:与对照组相比,试验组患者注药前玻璃体腔中VEGI浓度降低,IL-1β及VEGF浓度显著升高,组间比较差异有统计学意义(P<0.05); 试验组注药后随着时间延长及注药次数增加,IL-1β及VEGF浓度降低,VEGI浓度逐渐升高,差异有统计学意义(P<0.05); 临床观察提示:试验组注药后黄斑水肿程度较前减轻,试验2组远期效果好于试验1组(P<0.05)。

    结论:VEGI可能与VEGF及IL-1β协同作用参与了增殖性糖尿病视网膜病变的发生发展。

    Abstract:

    AIM: To explore the effects of intravitreous injection on vascular endothelial growth inhibitor(VEGI)and its relative cytokines in vitreous and to investigate its role in the pathogenesis of proliferative diabetic retinopathy(PDR).

    METHODS: Fifty patients with 68 eyes were randomly divided into 2 groups according its treatment situation. Thirty-four patients with 41 eyes were chosen as group one, who were treated with bevacizumab 1.25mg(0.05mL)per eye, and group 2 composed of 16 patients(27 eyes), who were accepted intravitreal injection of triamcinolone acetonide 4mg(0.1mL). Twenty patients(20 eyes), who were diagnosed as macula hole, were chosen for control group. Certain patients were collected as target population according to the inclusion criteria. VEGI, IL-1β and VEGF in vitreous were determined by ELISA, in which the samples of 0.3mL vitreous were collected before intravitreal injection or at 1, 3, 6mo post-injection in the two groups. And the data obtained between groups were compared by SPSS 19.0 statistical software.

    RESULTS: Significant difference was found between control group and experimental groups in which VEGI decreased while IL-1β and VEGF increased before injection(P<0.05). However, VEGI increased but IL-1β and VEGF decreased compared with control group after intravitreal injection(P<0.05). The clinical observation showed that the macula edema reduced in experimental groups post-injection, and experimental group 2 was better than experimental group 1 in the long-term results(P<0.05).

    CONCLUSION: VEGI is found accompanied with VEGF and IL-1β in the vitreous, and they may play an important role in the pathogenesis of PDR.

    参考文献
    相似文献
    引证文献
引用本文

石蕊,马勇,王峰,等.球内注药对增殖性糖尿病视网膜病变玻璃体液中VEGI表达的影响.国际眼科杂志, 2015,15(6):985-988.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2015-03-04
  • 最后修改日期:2015-05-13
  • 录用日期:
  • 在线发布日期: 2015-06-01
  • 出版日期:
文章二维码